ArticleAntibody therapeutics2023

Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5.

Kevin C Entzminger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.